Audeo Oncology (Audeo Oncology) Price-to-Owner-Earnings : (As of May. 14, 2024)

View and export this data going back to . Start your Free Trial

What is Audeo Oncology Price-to-Owner-Earnings?

As of today (2024-05-14), Audeo Oncology's share price is $0.00. Audeo Oncology does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.

The historical rank and industry rank for Audeo Oncology's Price-to-Owner-Earnings or its related term are showing as below:

AURX's Price-to-Owner-Earnings is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 28.12
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-14), Audeo Oncology's share price is $0.00. Audeo Oncology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2012 was $0.00. Therefore, Audeo Oncology's PE Ratio (TTM) for today is N/A.

As of today (2024-05-14), Audeo Oncology's share price is $0.00. Audeo Oncology's EPS without NRI for the trailing twelve months (TTM) ended in was $0.00. Therefore, Audeo Oncology's PE Ratio without NRI for today is N/A.

Audeo Oncology Price-to-Owner-Earnings Historical Data

The historical data trend for Audeo Oncology's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Audeo Oncology Price-to-Owner-Earnings Chart

Audeo Oncology Annual Data

Trend

Jun10

Jun11

Jun12

Price-to-Owner-Earnings

Audeo Oncology Quarterly Data
	Jun11	Mar12	Jun12	Sep12
Price-to-Owner-Earnings	-	-	-	-

Competitive Comparison of Audeo Oncology's Price-to-Owner-Earnings

For the Drug Manufacturers - General subindustry, Audeo Oncology's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Audeo Oncology's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Audeo Oncology's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Audeo Oncology's Price-to-Owner-Earnings falls into.

Audeo Oncology Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Audeo Oncology's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings	=	Share Price	/	Owner Earnings per Share (TTM)
	=	0.00	/	0.00
	=

Audeo Oncology (DELISTED:AURX) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.

Audeo Oncology Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Audeo Oncology's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.

Audeo Oncology (Audeo Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Audeo Oncology Inc (DELISTED:AURX) » Definitions » Price-to-Owner-Earnings

Traded in Other Exchanges

N/A

Address

Website

http://www.audeooncology.com

Audeo Oncology, Inc was incorporated in Delaware in June 2012. It is a late stage biopharmaceutical company utilizing its Hyaluronic Acid Chemotransport Technology, or HyACT, to target cancer drugs preferentially to tumor cells to enhance drug activity. HyACT is a flexible platform technology designed to increase the effectiveness of anti-cancer agents without increasing treatment toxicity. It seeks to reduce the risks related to drug development by using known anti-cancer drugs, and aim to enhance their commercial value by improving their effectiveness. The Company's lead HyACT product candidate, HA-Irinotecan, is currently in a pivotal Phase III clinical trial for metastatic colorectal cancer, or mCRC. HA-Irinotecan is also in an investigator-sponsored Phase II clinical trial for small cell lung cancer, or SCLC. It also has two other HyACT product candidates that have successfully completed Phase I clinical trials. In addition to its current clinical-stage product candidates, it aims to develop a pipeline of product candidates by exploiting its significant know-how in cancer stem cell biology and cancer metabolism combined with the Versatile Assembly on Stable Templates, or VAST, molecule drug discovery technology that it will in-license. The Company's lead product candidate is HyACT-targeted irinotecan, or HA-Irinotecan, for the treatment of mCRC. Irinotecan, which is marketed in major markets by Pfizer as Camptosar, is an off-patent chemotherapy drug widely used in the treatment of mCRC. Government authorities in the United States (including federal, state and local authorities) and in other countries extensively regulate the manufacture, research, clinical development, labeling, packaging, distribution, post-approval monitoring and reporting, advertising, promotion, export and import of pharmaceutical products, such as those it is developing.